Optimal antiplatelet therapy during percutaneous coronary interventions includes glycoprotein IIb/IIIa inhibitors just eliminate the infusion.
Mahmud
Ehtisham
E
Prasad
Anand
A
D015906:Angioplasty, Balloon, Coronary; D003131:Combined Modality Therapy; D003327:Coronary Disease / Q000628:therapy; D004334:Drug Administration Schedule; D000077542:Eptifibatide; D006470:Hemorrhage / Q000139:chemically induced / Q000453:epidemiology; D006801:Humans; D007262:Infusions, Intravenous; D010455:Peptides / Q000008:administration & dosage* / Q000009:adverse effects; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D015607:Stents
D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077542:Eptifibatide